BioAtla (BCAB) Other Non Operating Income (2020 - 2026)
BioAtla's (BCAB) quarterly Other Non Operating Income came in at $3.0 million in Q1 2026, up 30.0% year-on-year from $2.3 million in Q1 2025, and up 660.3% quarter-over-quarter from -$529000.0 in Q4 2025.
BioAtla (BCAB) Other Non Operating Income (2020 - 2026) Analysis & Trends
BioAtla's Other Non Operating Income history runs 7 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 30.0% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $382000.0, a 92.69% decrease from a year earlier, with the FY2025 full-year figure at -$302000.0, down 107.25% from the prior year.
- Other Non Operating Income improved to $3.0 million in Q1 2026 per BCAB's latest filing, from -$529000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $3.0 million in Q1 2026 and bottomed at -$2.0 million in Q3 2025.
- The 5-year median for Other Non Operating Income is $1.0 million (2022), against an average of $865411.8.
- Across the five-year window, Other Non Operating Income soared 1497.83% in 2023 and sank 390.79% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at $1.0 million in 2022, then soared by 58.41% to $1.6 million in 2023, then dropped by 15.58% to $1.4 million in 2024, then slumped by 138.9% to -$529000.0 in 2025, then soared by 660.3% to $3.0 million in 2026.
- Per Business Quant, the three latest BCAB Other Non Operating Income figures stand at $3.0 million (Q1 2026), -$529000.0 (Q4 2025), and -$2.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | BioAtla | 5.08 Mn | 5.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.96 Mn |
| Dec 31, 2025 | -529,000.00 |
| Sep 30, 2025 | -1.99 Mn |
| Jun 30, 2025 | -64,000.00 |
| Mar 31, 2025 | 2.28 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 684,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.70 Mn |
| Jun 30, 2023 | 1.45 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 400,000.00 |
| Jun 30, 2022 | 149,000.00 |
| Mar 31, 2022 | 92,000.00 |
| Sep 30, 2021 | 765,000.00 |
| Jun 30, 2021 | 79,000.00 |
| Mar 31, 2021 | 96,000.00 |